Advances in Heart Failure - Is It Time to Redefine Patient Selection for Sodium-Glucose Co-transporter 2 Inhibitors?

Published: 09 October 2020

  • Views:

    Views Icon 593
  • Likes:

    Heart Icon 7
  • episode_image
    16m 28s
    Part 4 Q&A Discussion
    Martin R Cowie, Faiez Zannad, Sanjay Kaul
Average (ratings)
No ratings
Your rating


This educational symposium was originally broadcast as part of the ESC 2020 Digital Congress.


The programme focuses on summarising recent data on SGLT2 inhibitors showing reductions in CV risk, HF hospitalisations  and mortality, as well as improved quality-of-life. The expert panel also discuss how these agents should be introduced into clinical practice and contemporary heart failure guidelines for both diabetics and non-diabetics.

This independent medical education symposium was supported by a grant from the Boehringer Ingelheim & Eli Lilly and Company alliance.

Learning Objectives

  • Discuss Current SGLT2 Data and Guideline Recommendations for Utilization in Heart Failure
  • Evaluate Emerging Data on the Treatment of Heart Failure with SGLT2 Inhibitors
  • Understand the Implications of Emerging Data on the Treatment of Heart Failure With SGLT2 Inhibitors

More from this programme

Part 1

SGLT2s as a Heart Failure Drug – How Did We Get Here?

Part 2

Emerging Data SGLT2 Inhibitors in Heart Failure

Part 3

Guidelines and Practice Implications

Part 4

Q&A Discussion

Part 5

Follow-up Peer-to Peer Discussion

Faculty Biographies

Sanjay Kaul

Sanjay Kaul

Professor of Medicine

Dr Sanjay Kaul is a Cardiologist at the Cedars-Sinai Medical Center, US where he is also a Professor of Medicine. Dr Kaul received his medical training at the Government Medical College of the University of Kashmir in India.

Dr Kaul is a Fellow of the American Heart Association Councils on Circulation and Arteriosclerosis and Thrombosis, and a Fellow of the American College of Cardiology.

Dr Kaul’s clinical interests are in preventive cardiovascular medicine, diabetes, coronary artery disease. His research interests lie in the fields of acute coronary syndromes, clinical trial and statistical methodology and evidence-based medicine.

View full profile